Stock A950210 PRESTIGE BIOPHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Prestige BioPharma Limited

Equities

A950210

KR8702070002

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 14/05/2024 am IST 		5-day change 1st Jan Change
7,980 KRW 0.00% Intraday chart for Prestige BioPharma Limited -1.48% -15.82%
2023 Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer CI
2023 Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit CI

Valuation

Fiscal Period: June 2021 2022 2023
Capitalization 1 3,96,635 1,37,620 1,13,582
Enterprise Value (EV) 1 -54,947 -1,61,400 -1,03,457
P/E ratio -230 x -3.02 x 32.3 x
Yield - - -
Capitalization / Revenue - - 70,18,10,622 x
EV / Revenue - - -63,92,52,890 x
EV / EBITDA 3.29 x 1.36 x -8.16 x
EV / FCF 24,59,475 x 14,09,329 x -1,27,06,238 x
FCF Yield 0% 0% -0%
Price to Book 17.2 x 8 x 6.3 x
Nbr of stocks (in thousands) 12,019 12,019 12,019
Reference price 2 33,000 11,450 9,450
Announcement Date 16/09/21 20/09/22 18/09/23
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2020 2021 2022 2023
Net sales - - - 161.8
EBITDA 1 -11,708 -16,717 -1,18,822 12,684
EBIT 1 -12,893 -18,384 -1,22,689 1,034
Operating Margin - - - 639.01%
Earnings before Tax (EBT) 1 -14,898 -7,357 -2,10,649 -2,095
Net income 1 -14,997 -7,391 -2,11,450 17,569
Net margin - - - 10,855.89%
EPS 2 -351.6 -143.2 -3,796 292.4
Free Cash Flow - -22,341 -1,14,523 8,142
FCF margin - - - 5,031.02%
FCF Conversion (EBITDA) - - - 64.19%
FCF Conversion (Net income) - - - 46.34%
Dividend per Share - - - -
Announcement Date 16/09/21 16/09/21 20/09/22 18/09/23
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: June 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 45,521 4,51,582 2,99,020 2,17,039
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - -22,341 -1,14,523 8,142
ROE (net income / shareholders' equity) - -2.07% -42.1% -0.59%
ROA (Net income/ Total Assets) - -3.01% -13.9% 0.1%
Assets 1 - 2,45,807 15,22,144 1,68,77,319
Book Value Per Share 2 3,082 1,913 1,431 1,499
Cash Flow per Share 2 1,028 1,527 894.0 416.0
Capex 1 1,340 949 56,429 48,363
Capex / Sales - - - 29,882.73%
Announcement Date 16/09/21 16/09/21 20/09/22 18/09/23
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
PRESTIGE BIOPHARMA LIMITED Stock Prestige BioPharma Limited
-15.82% 7.01Cr
CSL LIMITED Stock CSL Limited
-1.36% 8.94TCr
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 4.07TCr
BIOGEN INC. Stock Biogen Inc.
-12.32% 3.28TCr
UCB Stock UCB
+52.41% 2.5TCr
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-17.39% 1.53TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.45% 1.16TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-10.48% 1.15TCr
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.14% 898.19Cr
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-7.72% 822.67Cr
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A950210 Stock
  4. Financials Prestige BioPharma Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW